Provides Business Update FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today reported that management’s discussion and analysis of financial condition...
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced that it has taken steps to mitigate the impact of the novel coronavirus SARS-CoV-2...
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred...
– Reports audited financial results for the Fourth Quarter and Full Year ended December 31, 2019 – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced the sale of its 12% equity interest in Cannara Biotech Inc. (CSE: LOVE) ("Cannara") to a...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company") announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, accompanied by FSD...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”) and Solarvest BioEnergy Inc. (TSX-V: SVS) (“Solarvest”) (collectively, the “Parties”), are pleased to announce that, further...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 16.225 | 16.225 | 16.225 | 924 | 16.225 | DE |
4 | 0 | 0 | 16.225 | 16.225 | 16.225 | 1003 | 16.225 | DE |
12 | 0 | 0 | 16.225 | 16.225 | 16.225 | 1246 | 16.225 | DE |
26 | 0 | 0 | 16.225 | 16.225 | 16.225 | 1840 | 16.225 | DE |
52 | -0.2275 | -1.3827685762 | 16.4525 | 16.7 | 16.225 | 28477 | 16.34139076 | DE |
156 | 7.581 | 87.7024525683 | 8.644 | 20.21 | 7.151 | 84436 | 14.39264098 | DE |
260 | 6.2725 | 63.0243657373 | 9.9525 | 20.21 | 6.2125 | 93576 | 11.66593284 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約